(Q35118033)

6 August 2017

1 reference

title

Biomarkers in drug discovery and development: from target identification through drug marketing (English)

1 reference

6 August 2017

Biomarkers in Drug Discovery and Development: From Target Identification through Drug Marketing (English)

1 reference

https://api.crossref.org/works/10.1177/0091270003252480

29 December 2023

0 references

1 reference

1 reference

https://api.crossref.org/works/10.1177/0091270003252480

29 December 2023

author name string

Wayne A. Colburn

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12723454

29 December 2023

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=12723454

29 December 2023

publication date

1 April 2003

1 reference

full work available at URL

6 August 2017

https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1177%2F0091270003252480

1 reference

https://api.crossref.org/works/10.1177/0091270003252480

https://accp1.onlinelibrary.wiley.com/doi/pdf/10.1177/0091270003252480

29 December 2023

1 reference

https://api.crossref.org/works/10.1177/0091270003252480

The Journal of Clinical Pharmacology

29 December 2023

published in

1 reference

6 August 2017

43

1 reference

6 August 2017

4

1 reference

6 August 2017

329-341

1 reference

Biomarkers and surrogate endpoints: preferred definitions and conceptual framework

6 August 2017

1 reference

https://api.crossref.org/works/10.1177%2F0091270003252480

Surrogate endpoints in clinical trials: definition and operational criteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270003252480

Early clinical trials of chemopreventive and biologic agents: Designs, populations, and endpoints

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270003252480

Selecting and validating biologic markers for drug development

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270003252480

The contribution of clinical pharmacology surrogates and models to drug development--a critical appraisal

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270003252480

Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270003252480

An approach to the validation of markers for use in AIDS clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270003252480

Toxicoproteomics -- a new preclinical tool

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270003252480

Searching for pharmacogenomic markers: the synergy between omic and hypothesis-driven research

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270003252480

Use of proteomic patterns in serum to identify ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270003252480

Role of modelling and simulation in Phase I drug development

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270003252480

Drugs and endogenous ligands compete for receptor occupancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270003252480

Pharmacokinetic-pharmacodynamic modelling in the early development phase of anti-psychotics: a comparison of the effects of clozapine, S 16924 and S 18327 in the EEG model in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270003252480

Pharmacodynamic modeling of lansoprazole using an indirect irreversible response model

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270003252480

Measurement validity in physical therapy research.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270003252480

Pharmacokinetic/pharmacodynamic modeling in drug development

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270003252480

Pharmacometrics: modelling and simulation tools to improve decision making in clinical drug development.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270003252480

The endogenous cannabinoid system and brain development

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270003252480

Agmatine: an endogenous ligand at imidazoline receptors is a novel neurotransmitter

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270003252480

Pharmacokinetic-pharmacodynamic modelling of morphine transport across the blood-brain barrier as a cause of the antinociceptive effect delay in rats--a microdialysis study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270003252480

Surrogate biochemical markers: precise measurement for strategic drug and biologics development.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270003252480

Validation of immunoassays for bioanalysis: a pharmaceutical industry perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270003252480

A randomized, double-blind trial of the effect of glucocorticoid, antileukotriene and beta-agonist treatment on IL-10 serum levels in children with asthma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270003252480

Interferon-gamma secretion of peripheral blood CD8+ T lymphocytes in patients with bronchial asthma: in vitro stimulus determines cytokine production

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270003252480

Association of vascular endothelial growth factor expression with tumor angiogenesis and with early relapse in primary breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270003252480

Common practice in molecular biology may introduce statistical bias and misleading biological interpretation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270003252480

Section 1C: Assessment of the functional activity and IgG Fc receptor utilisation of 64 IgG Rh monoclonal antibodies. Coordinator's report.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270003252480

A Pearson-type goodness-of-fit test for stationary and time-continuous Markov regression models.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270003252480

Acute migraine treatment outcome measures: a clinician's view

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270003252480

21 January 2018

Measuring asthma control

1 reference

https://api.crossref.org/works/10.1177%2F0091270003252480

The biology of the opioid growth factor receptor (OGFr)

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270003252480

Functional analysis of chromatin assembled in synthetic nuclei.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270003252480

Multimarker approach to risk stratification in non-ST elevation acute coronary syndromes: simultaneous assessment of troponin I, C-reactive protein, and B-type natriuretic peptide.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270003252480

Serum biomarkers of non-neuron-endocrine origin in small-cell lung cancer: a 16-year study on carcinoembryonic antigen, tissue polypeptide antigen and lactate dehydrogenase

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270003252480

Tissue microarray sampling strategy for prostate cancer biomarker analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270003252480

Standardization, analytical validation, and quality control of intermediate endpoint biomarkers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270003252480

Differences between local investigator and core laboratory interpretation of the admission electrocardiogram in patients with unstable angina pectoris or non-Q-wave myocardial infarction (a Thrombin Inhibition in Myocardial Ischemia [TRIM] substudy)

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270003252480

One core laboratory at two international sites, is that feasible? An inter-core laboratory and intra-observer variability study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270003252480

A regulatory perspective on pharmacokinetic/pharmacodynamic modelling

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270003252480

Use of biomarkers and surrogate endpoints in drug development and regulatory decision making: criteria, validation, strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270003252480

Prediction of the outcome of a phase 3 clinical trial of an antischizophrenic agent (quetiapine fumarate) by simulation with a population pharmacokinetic and pharmacodynamic model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270003252480

Simulation of clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270003252480

Mechanism-based pharmacodynamic modeling

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270003252480

Surrogate markers and clinical pharmacology

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270003252480

Can pharmacogenomics make a difference in drug development?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270003252480

Pharmacokinetic/pharmacodynamic modeling of antitumor agents encapsulated into liposomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270003252480

Sensitivity analysis of pharmacokinetic and pharmacodynamic systems: I. A structural approach to sensitivity analysis of physiologically based pharmacokinetic models

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270003252480

Measurement of urinary F(2)-isoprostanes as markers of in vivo lipid peroxidation-A comparison of enzyme immunoassay with gas chromatography/mass spectrometry

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270003252480

Workshop on bioanalytical methods validation for macromolecules: summary report

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270003252480

Reduced interleukin-18 levels in BAL specimens from patients with asthma compared to patients with sarcoidosis and healthy control subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270003252480

Tumor angiogenesis in breast cancer: its importance as a prognostic indicator and the association with vascular endothelial growth factor expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270003252480

A sensitive fluorometric enzyme-linked immunosorbent assay that measures vascular endothelial growth factor165 in human plasma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270003252480

On the standardization of total prostate-specific antigen: an exercise with two reference preparations

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270003252480

Revisiting the anticardiolipin test and its standardization

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270003252480

Strategies for genetic mapping of categorical traits

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270003252480

Evaluation of tumour angiogenesis as a prognostic marker in malignant mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270003252480

Cryopreserving whole blood for functional assays using viable lymphocytes in molecular epidemiology studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270003252480

Clinical trial simulation of docetaxel in patients with cancer as a tool for dosage optimization

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270003252480

Validation of markers for their relevance to health and disease

21 January 2018

5

1 reference

https://api.crossref.org/works/10.1177/0091270003252480

Advantages and synergism of combined pharmacokinetic and pharmacodynamic studies during drug development

29 December 2023

30

1 reference

https://api.crossref.org/works/10.1177/0091270003252480

Methodological aspects in the analysis of spontaneously produced sputum

29 December 2023

48

1 reference

https://api.crossref.org/works/10.1177/0091270003252480

Flow cytometric microsphere-based immunoassay: analysis of secreted cytokines in whole-blood samples from asthmatics

29 December 2023

51

1 reference

https://api.crossref.org/works/10.1177/0091270003252480

A phase II study of razoxane, an antiangiogenic topoisomerase II inhibitor, in renal cell cancer with assessment of potential surrogate markers of angiogenesis

29 December 2023

52

1 reference

https://api.crossref.org/works/10.1177/0091270003252480

Validation of biomarkers as early predictors of disease

29 December 2023

73

1 reference

https://api.crossref.org/works/10.1177/0091270003252480

29 December 2023

Identifiers

1 reference

6 August 2017

1 reference